Source:http://linkedlifedata.com/resource/pubmed/id/20664989
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
3
|
| pubmed:dateCreated |
2010-7-28
|
| pubmed:abstractText |
We evaluated the safety of, and clinical and immune responses to personalized peptide vaccination with gemcitabine (GEM) as the first line therapy in patients with non-resectable pancreatic cancer. Pre-vaccination peripheral blood mononuclear cells (PBMCs) and plasma were prepared to examine cellular and humoral responses to 14 and 16 peptides in human leukocyte antigen (HLA)-A24+ or -A2+ patients, respectively. Only the reactive peptides (maximum of 4) were administered weekly at 3 mg/peptide. GEM was administered at 1000 mg/m(2) per week for 3 weeks, followed by 1 week of rest. Twenty-one patients with untreated and non-resectable pancreatic cancer were enrolled. The combination therapy was generally well tolerated. Boosting of cellular and humoral responses to the vaccinated peptides was observed in the post-vaccination (eighth) PBMCs and plasma from 14 of 18 and 13 of 18 patients tested, respectively. The best clinical responses were 7 cases of partial response, 9 cases of stable disease, and 5 cases of progressive disease. Median survival time of all 21 patients was 9.0 months (95% CI, 6-15.5 months) with a one year survival rate of 38%. Immune boosting in both cellular and humoral responses was well correlated with overall survival with a hazard ratio of 0.2 (95% CI, 0.06-0.73; log-rank p=0.0239). These results suggest a potential clinical benefit of this combination therapy for non-resectable pancreatic cancer patients as the first line therapy. Further exploration of this approach is warranted.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antimetabolites, Antineoplastic,
http://linkedlifedata.com/resource/pubmed/chemical/Cancer Vaccines,
http://linkedlifedata.com/resource/pubmed/chemical/Deoxycytidine,
http://linkedlifedata.com/resource/pubmed/chemical/HLA Antigens,
http://linkedlifedata.com/resource/pubmed/chemical/Vaccines, Subunit,
http://linkedlifedata.com/resource/pubmed/chemical/gemcitabine
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Sep
|
| pubmed:issn |
1791-2431
|
| pubmed:author |
pubmed-author:ItohKyogoK,
pubmed-author:KomatsuNobukazuN,
pubmed-author:KwonA-HonAH,
pubmed-author:MineTakashiT,
pubmed-author:NoguchiMasanoriM,
pubmed-author:SatoiSoheiS,
pubmed-author:ShiomiHisanoriH,
pubmed-author:TaniTohruT,
pubmed-author:ToyokawaHideyoshiH,
pubmed-author:YamadaAkiraA,
pubmed-author:YamamotoTomohisaT,
pubmed-author:YanagimotoHiroakiH
|
| pubmed:issnType |
Electronic
|
| pubmed:volume |
24
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
795-801
|
| pubmed:meshHeading |
pubmed-meshheading:20664989-Aged,
pubmed-meshheading:20664989-Aged, 80 and over,
pubmed-meshheading:20664989-Antimetabolites, Antineoplastic,
pubmed-meshheading:20664989-Cancer Vaccines,
pubmed-meshheading:20664989-Deoxycytidine,
pubmed-meshheading:20664989-Female,
pubmed-meshheading:20664989-HLA Antigens,
pubmed-meshheading:20664989-Humans,
pubmed-meshheading:20664989-Immunity, Cellular,
pubmed-meshheading:20664989-Immunity, Humoral,
pubmed-meshheading:20664989-Japan,
pubmed-meshheading:20664989-Kaplan-Meier Estimate,
pubmed-meshheading:20664989-Male,
pubmed-meshheading:20664989-Middle Aged,
pubmed-meshheading:20664989-Neoplasm Staging,
pubmed-meshheading:20664989-Pancreatic Neoplasms,
pubmed-meshheading:20664989-Time Factors,
pubmed-meshheading:20664989-Treatment Outcome,
pubmed-meshheading:20664989-Vaccines, Subunit
|
| pubmed:year |
2010
|
| pubmed:articleTitle |
A phase II study of personalized peptide vaccination combined with gemcitabine for non-resectable pancreatic cancer patients.
|
| pubmed:affiliation |
Department of Surgery, Kansai Medical University, Hirakata, Japan.
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase II
|